Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/13/2018 02/14/2018 02/15/2018 02/16/2018 02/20/2018 Date
111.86(c) 113.08(c) 114.9(c) 118.6(c) 118.78 Last
5 316 151 6 189 148 7 401 127 8 828 651 5 712 971 Volume
-0.06% +1.09% +1.61% +3.22% +0.15% Change
More quotes
Financials ($)
Sales 2018 32 143 M
EBIT 2018 14 063 M
Net income 2018 10 260 M
Debt 2018 22 102 M
Yield 2018 2,64%
Sales 2019 34 458 M
EBIT 2019 16 289 M
Net income 2019 11 704 M
Debt 2019 16 601 M
Yield 2019 2,98%
P/E ratio 2018 18,05
P/E ratio 2019 15,70
EV / Sales2018 6,58x
EV / Sales2019 5,98x
Capitalization 189 B
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
04/12Ex-dividend day
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
04:45pABBVIE : Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Tri..
AQ
04:44pABBVIE : Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endosc..
AQ
11:21aABBVIE : reports more solid data for would-be psoriasis blockbuster
AQ
02/19ABBVIE : Increases Dividend and Announces New Stock Repurchase Program
AQ
02/19ABBVIE : Recognized as a FORTUNE 100 Best Company to Work For
AQ
02/18ABBVIE : Stocks’ Win Streak Extends to Six Days
AQ
02/17ABBVIE : Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Tri..
PU
02/17ABBVIE : Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Derm..
PU
02/17ABBVIE : Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endosc..
AQ
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
12:41pMERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE 
ABBVIE  - 2015
A likely recovery
BUY
More Strategies
Latest Tweets
05:46pWith $69M Deal, @abbvie Turns to Voyager for an #Alzheimer’s #GeneTherapy |  
05:37pAnalysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (N.. 
05:36p?NICE PACE TO FLOW, MOSTLY MOMENTUM SWEEPERS WITH A FOCUS ON TECH IN THE EARL.. 
03:42p$ABBV REPEAT BULL SWEEPERS DETECTED EARLY 
03:08p$VYGR: Voyager Therapeutics enters exclusive strategic collaboration and opti.. 
More tweets
Qtime:220
News from SeekingAlpha
10:26aBiotech Forum Daily Digest For February 20th 
07:41aMultiple Double-Digit Payout Increases In The First 2 Weeks Of February 
07:40aVoyager Therapeutics inks deal with AbbVie to develop anti-tau antibodies in .. 
02/19Healthcare In Transition 
02/19YOUR DAILY PHARMA SCOOP : AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Ce.. 
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE16.93%189 337
MERCK KGAA-8.06%13 280
KYOWA HAKKO KIRIN CO LTD5.76%12 664
JAZZ PHARMACEUTICALS PLC8.31%8 738
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.51%6 883
CONVATEC GROUP3.26%5 818